Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) General Counsel Jason B. Shandell sold 25,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $18.44, for a total transaction of $461,000.00. Following the sale, the general counsel now owns 163,898 shares of the company’s stock, valued at $3,022,279.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of AMPH traded down $0.05 during mid-day trading on Friday, reaching $18.66. The company’s stock had a trading volume of 152,200 shares, compared to its average volume of 175,544. The stock has a market cap of $882.47 million, a PE ratio of 88.86 and a beta of 1.16. The company has a current ratio of 3.11, a quick ratio of 1.84 and a debt-to-equity ratio of 0.13. Amphastar Pharmaceuticals Inc has a 52 week low of $16.71 and a 52 week high of $25.43. The company’s fifty day moving average price is $19.07 and its two-hundred day moving average price is $20.00.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.10 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.08 by $0.02. The firm had revenue of $80.14 million during the quarter, compared to analyst estimates of $78.53 million. Amphastar Pharmaceuticals had a net margin of 15.77% and a return on equity of 5.07%. The business’s quarterly revenue was up 6.1% on a year-over-year basis. During the same period in the previous year, the business posted $0.12 EPS. Research analysts anticipate that Amphastar Pharmaceuticals Inc will post 0.05 EPS for the current year.
Several equities research analysts have issued reports on AMPH shares. Zacks Investment Research lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, October 24th. ValuEngine upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, December 3rd. TheStreet lowered shares of Amphastar Pharmaceuticals from a “b-” rating to a “c” rating in a research report on Thursday, November 7th. Finally, BidaskClub lowered shares of Amphastar Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company’s stock. Amphastar Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $24.05.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.
Featured Article: Why does a company issue an IPO?
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.